Heparin and Low-Molecular-Weight Heparins

Heparin and the low-molecular-weight heparins (LMWHs) are parenteral anticoagulants that work indirectly, by binding and potentiating the natural inhibitor antithrombin. Unfractionated heparin is a heterogeneous mixture of glycosaminoglycan chains, while LMWHs are shorter fragments with a more predictable, factor Xa-weighted effect. Both are foundational agents for the rapid anticoagulation needed in acute thrombotic settings.

Definition

Heparins are indirect, parenteral anticoagulants that bind antithrombin and accelerate its inactivation of thrombin and factor Xa; low-molecular-weight heparins are depolymerised fractions with relatively greater anti-Xa activity and more predictable pharmacokinetics.

Scope

This entry covers the mechanism of heparin and LMWHs as antithrombin potentiators, the pharmacological differences between unfractionated and low-molecular-weight preparations, the principles of laboratory monitoring, and the characteristic adverse effect of heparin-induced thrombocytopenia. It is a reference description of the drug class, not dosing or treatment guidance.

Core questions

• How does heparin produce anticoagulation indirectly through antithrombin rather than acting on clotting factors itself?
• What pharmacological differences distinguish unfractionated heparin from low-molecular-weight heparins?
• Why is unfractionated heparin monitored while low-molecular-weight heparins are often given without routine monitoring?
• What is heparin-induced thrombocytopenia, and why is it a paradoxical prothrombotic complication?

Key concepts

• Antithrombin potentiation
• Pentasaccharide binding sequence
• Anti-thrombin (anti-IIa) versus anti-factor-Xa activity
• Unfractionated heparin versus low-molecular-weight heparin
• Activated partial thromboplastin time and anti-Xa monitoring
• Protamine reversal
• Heparin-induced thrombocytopenia (HIT)

Mechanisms

Heparin binds to antithrombin through a specific pentasaccharide sequence, inducing a conformational change that greatly accelerates antithrombin's inactivation of thrombin (factor IIa) and factor Xa. Inhibiting thrombin requires heparin chains long enough to bridge antithrombin and thrombin simultaneously, so the short chains of LMWHs preferentially inhibit factor Xa over thrombin, giving a higher anti-Xa to anti-IIa ratio. Hirsh and colleagues detail how this difference, together with reduced binding to plasma proteins and cells, gives LMWHs more predictable dose-response and a longer half-life than unfractionated heparin. Unfractionated heparin is typically monitored by the activated partial thromboplastin time or anti-Xa assay and can be reversed with protamine, while LMWHs are only partially reversed by protamine.

Clinical relevance

Heparins are widely used to provide rapid anticoagulation in venous thromboembolism, acute coronary syndromes, and during procedures requiring extracorporeal circulation, and their pharmacology underpins the ACCP parenteral anticoagulant guidance. This entry explains how the class works and how its preparations differ; it is intended as reference education and not as a basis for dosing or individual treatment decisions.

Epidemiology

Heparins are among the most frequently administered parenteral drugs in hospitalised patients. Bleeding is the principal dose-related adverse effect, and heparin-induced thrombocytopenia, although uncommon, is a clinically important immune-mediated complication that occurs more often with unfractionated than with low-molecular-weight heparin.

History

Heparin was discovered in 1916 and entered clinical use in the late 1930s and 1940s as the first practical rapid anticoagulant. Recognition that depolymerised fragments retained anti-Xa activity with more predictable pharmacokinetics led to the development of low-molecular-weight heparins in the 1980s, which progressively replaced unfractionated heparin for many indications because they could often be given subcutaneously without routine monitoring.

Debates

When is routine anticoagulant monitoring needed for heparins?

Unfractionated heparin's variable, protein-binding-dependent response generally requires laboratory monitoring, whereas low-molecular-weight heparins are usually given in fixed weight-based regimens without routine monitoring, though monitoring is discussed for selected populations.

Key figures

• Jack Hirsh
• Theodore Warkentin
• Gowthami Arepally

Seminal works

• hirsh-2001-heparin
• arepally-2006

Frequently asked questions

How is low-molecular-weight heparin different from unfractionated heparin?

Low-molecular-weight heparin consists of shorter chains that preferentially inhibit factor Xa over thrombin, bind less to plasma proteins, and therefore have a more predictable dose-response and longer half-life, allowing fixed weight-based subcutaneous use without routine monitoring in many settings.

What is heparin-induced thrombocytopenia?

It is an immune-mediated reaction in which antibodies against heparin-platelet factor 4 complexes activate platelets, causing a fall in platelet count and, paradoxically, an increased risk of thrombosis; it occurs more commonly with unfractionated than low-molecular-weight heparin.